Project description
A silver bullet for staph infections may be around the corner
Since the discovery of penicillin in 1928, we have come to take antibiotics and their ability to cure us of many infectious diseases for granted. Antibiotic resistance is changing all that. Some strains of bacteria have become resistant to practically all commonly available drugs and infections that were easily cured have become killers once again. StaphIMPACT has a proprietary endolysin, an enzyme that causes targeted bacterial cells to rupture (or lyse) at the end of the cell cycle. It is extremely effective against Staphylococcus aureus (S. aureus), including the resistant strain, and has been commercially available since 2013. With EU funding, StaphIMPACT is scaling up production capacity and strengthening partnerships to provide much-needed relief from inflammatory skin conditions.
Objective
According to the WHO, antibiotic resistance is one of humanity’s biggest health threats, claiming ~10 million extra deaths per year and US$100 trillion by 2050, unless alternatives to antibiotics are developed. Micreos has developed the world’s first targeted antibacterial products, set to replace antibiotics. With its endolysin technology, for the first time it is possible to kill only the unwanted bacteria, regardless of resistance. Micreos’ endolysin technology was chosen as Europe’s most relevant Innovation 2018 (Ideas from Europe). Its first lead endolysin, SA.100 kills only Staphylococcus aureus, including the resistant MRSA. Soft-launched under the Gladskin brand in the Netherlands, it’s having life-changing impact for thousands of people with inflammatory skin conditions caused or aggravated by S. aureus, including eczema, acne, rosacea and Hyper IgE syndrome. Micreos also develops products for diabetic wound infections and a skin cancer triggered by S. aureus. Micreos owns all relevant IP and know-how on its technology and produces its compounds and Gladskin products at small-scale at its facilities in the Netherlands. With this SMEi, Micreos prepares for full roll-out into the EU markets of its SA.100/Gladskin. This includes scale-up of production capacity, strengthening clinical evidence and communication of results to KOLs and relevant stakeholders. Leading pharma and cosmetics companies have expressed interest to in-license Micreos’ technology for particular indications. Relevant markets are the consumer’s skin care market ($177b by 2024; CAGR 4.7%) and dermatology market ($19.8b by 2023; CAGR 9.1%.). Own contribution by Micreos for this SMEi is already secured. This SMEi enables Micreos to take final steps for EU-wide roll-out, driving employment growth and company profitability, and helping people suffering from inflammatory skin conditions.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology skin cancer
- medical and health sciences clinical medicine dermatology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- social sciences economics and business business and management employment
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2585EV S GRAVENHAGE
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.